**Experience certainty** 





## Confidentiality Statement






This document contains information which is commercially confidential to Tata Consultancy Services Ltd. ("TCS") and is provided for the sole purpose of permitting the recipient to evaluate the proposal submitted within the document. In consideration of the receipt of this document, the recipient agrees to maintain the information it contains in confidence and not to reproduce or otherwise disclose the contents of this document to any person outside the recipient's evaluation team or nominated advisors. The document may not be used, reproduced or disclosed to others, except as specifically permitted by TCS in writing. The recipient of this document, by its retention and use, agrees to take reasonable endeavours to protect the document and the information it contains from loss or theft.

© 2017 - TATA Consultancy Services Limited (TCS)

#### About IG

- SDTM IG guides the organizations on structure and format of standard clinical trial tabulation datasets.
- These datasets are submitted to a regulatory authority such as the US Food and Drug Administration (FDA).
- Current version of IG is 3.2
- The SDTMIG should be used in close concert with the current version of the CDISC Study Data Tabulation Model (SDTM, available at http://www.cdisc.org/sdtm)



#### SDTM IG Sections

- Section 1 Introduction:
  - Overall introduction
  - Describes changes from prior versions.
- Section 2 Fundamentals of the SDTM
  - Basic concepts of the SDTM
  - How this implementation guide should be used in concert with the SDTM.
- Section 3 Submitting Data in Standard Format, explains how to describe metadata for regulatory submissions, and how to assess conformance with the standards.
- Section 4 Assumptions for Domain Models, describes basic concepts, business rules, and assumptions that should be taken into consideration before applying the domain models.
- Section 5 Models for Special-Purpose Domains, describes special-purpose domains, including Demographics,
  Comments, Subject Visits, and Subject Elements.
- Section 6 Domain Models Based on the General Observation Classes, provides specific metadata models based on the three general observation classes, along with assumptions and example data.
- Section 7 Trial Design Datasets, provides specific metadata models, assumptions, and examples.
- Section 8 Representing Relationships and Data, describes how to represent relationships between separate domains, datasets, and/or records, and information to help sponsors determine where data belongs in the SDTM.

Appendices provide additional background material and describe other supplemental material relevant to implementation.

# Takeaway from EACH SECTION OF IG

Section	I will learn
1,2,3	The key concepts for <u>preparing domains</u> and <u>submitting</u> data to regulatory authorities.
4	What are the assumption while creating different domains
5	Models for <b>Special Purpose domains</b> (You can refer back to Section 4 to link section 4 & 5) (implementation examples for each domain help to understand how to apply the domain models for specific types of data)
6	Domain Models based on <b>General Observation classes</b> (implementation examples for each domain help to understand how to apply the domain models for specific types of data)
7	Trial Design Domains to understand the fundamentals of the Trial Design Model
8	Representing <b>Relationships and Data</b> helps to understand how to express relationships between datasets, records and additional variables not specifically defined in the models.
Appendices	Appendix C – Controlled Terminology, in particular, describes how CDISC Terminology is centrally managed by the CDISC Controlled Terminology Team. CDISC terminology is updated on a quarterly



## Reference PAPER



### References

https://www.pharmasug.org/proceedings/2016/DS/PharmaSUG-2016-DS04.pdf

https://www.cdisc.org/standards/foundational/sdtmig

Experience certainty.



# Thank You